The strong finish to 2022 was clearly overshadowed by a disappointing 2023 EBITDA margin guidance, ...
Redeye provides a preview ahead of Embracer Group’s Q3 2022/2023e report, due on 16th of February.
Beijer Group reported an order intake of about SEK603m and sales of close to SEK589m, translating in...
We terminate commissioned coverage on Orexo. Note that estimates and information have not been updat...
Preliminary Q4 sales in line with ABGSCe, EBIT slightly above CEO Christian Sundin leaves after 16 y...
Ultimovacs has announced that patient enrolment has been completed (n=118) for the ongoing Phase II ...
Redeye endorses the news that Egetis Therapeutics has conducted a directed share issue of SEK210m an...
At first glance, Netcompany 2022 annual report looks as a positive read when it comes to Q4 performa...
Redeye shares its preview of BONESUPPORT’s Q4 2022e results and anticipates another record quarter.
Redeye ceases its coverage of Sileon due to the end of the contractual period.
Redeye states its view on today’s December ARR update from Hoylu that closing its Q4 2022 figures.
Higher net financials weigh on '23e-'24e net profit.
Mangold Insight initiate coverage of the biotechnology company Biosergen with a buy recommendation a...
Adj. EBITA SEK 331m (+5% vs. cons. 315m) We expect cons.
Elanders presented yet another solid report for Q4 2022, growing adjusted EBIT by 37% y/y.
Q4 report on Thursday, 26 January Receives order in Reactive Recycling worth ~SEK 2m We expect sales...
Lipigon aviserade under förra veckan positiva säkerhetsdata med Lipisense i klinisk fas I.
Redeye comments on Jondetech’s announcement of its restructuring program.
Good momentum for its leased-capacity business We remove Ovzon-3 from '23e as we turn more prudent 1...
We see tailwinds from recent geopolitical events Ovzon’s newsflow has been positive lately.
